Fragment-to-Lead Medicinal Chemistry Publications in 2015

被引：52

作者：

Johnson, Christopher N. ^{[1
]}

Erlanson, Daniel A. ^{[2
]}

Murray, Christopher W. ^{[1
]}

Rees, David C. ^{[1
]}

机构：

[1] Astex Pharmaceut, 436 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0QA, England

[2] Carmot Therapeut Inc, 409 Illinois St, San Francisco, CA 94158 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2017年 / 60卷 / 01期

关键词：

STRUCTURE-BASED DESIGN; ATAD2 BROMODOMAIN INHIBITORS; PROTEIN-PROTEIN INTERACTIONS; SMALL-MOLECULE INHIBITORS; LEUCINE-ZIPPER KINASE; DRUG DISCOVERY; PARALLEL SYNTHESIS; POTENT; IDENTIFICATION; OPTIMIZATION;

D O I：

10.1021/acs.jmedchem.6b01123

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Fragment-based drug discovery (FBDD) is now well-established as a technology for generating new chemical leads and drags. This. Miniperspective provides a tabulated overview of the fragment-to-lead literature published in the year 2015, together with a commentary on trends observed across the FBDD field during this time. It is hoped that this tabulated summary will provide a useful point of reference for both FBDD practitioners and the wider medicinal Chemistry community.

引用

页码：89 / 99

页数：11

共 50 条

[41] From virtuality to reality - Virtual screening in lead discovery and lead optimization: A medicinal chemistry perspective
Rester, Ulrich
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2008, 11 (04) : 559 - 568
[42] Focusing on Relevance: CETSA-Guided Medicinal Chemistry and Lead Generation
Lundgren, Stina
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (05): : 690 - 693
[43] Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective
Zhao, Hongyu
DRUG DISCOVERY TODAY, 2007, 12 (3-4) : 149 - 155
[44] Computational medicinal chemistry in fragment-based drug discovery: what, how and when
Rabal, Obdulia
Urbano-Cuadrado, Manuel
Oyarzabal, Julen
FUTURE MEDICINAL CHEMISTRY, 2011, 3 (01) : 95 - 134
[45] How to report and discuss ADME data in medicinal chemistry publications: in vitro data or in vivo extrapolations?
Svennebring, Andreas M.
FUTURE MEDICINAL CHEMISTRY, 2015, 7 (03) : 259 - 267
[46] Advances and New Perspectives in Medicinal Chemistry Engineering and Bioinformatics (from IWBBIO 2015)
Ortuno, Francisco M.
Valenzuela, Olga
Rojas, Ignacio
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (14) : 1597 - 1598
[47] Medicinal Chemistry Optimization of a Diaminopurine Chemotype: Toward a Lead for Trypanosoma brucei Inhibitors
Singh, Baljinder
Diaz-Gonzalez, Rosario
Ceballos-Perez, Gloria
Rojas-Barros, Domingo I.
Gunaganti, Naresh
Gillingwater, Kirsten
Santos Martinez-Martinez, Maria
Manzano, Pilar
Navarro, Miguel
Pollastri, Michael P.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (17) : 9912 - 9927
[48] Medicinal Chemistry - XXth International Symposium Lead finding strategies and kinase selectivity
Rotella, David P.
IDRUGS, 2008, 11 (11) : 774 - 778
[49] Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry
Munson, Mark
Lieberman, Harvey
Tserlin, Elina
Rocnik, Jennifer
Ge, Jie
Fitzgerald, Maria
Patel, Vinod
Garcia-Echeverria, Carlos
DRUG DISCOVERY TODAY, 2015, 20 (08) : 978 - 987
[50] An Overview on Glyeco-Macrcocycles: Potential New Lead and their Future in Medicinal Chemistry
Singh, Kartikey
Tripathi, Rama Pati
CURRENT MEDICINAL CHEMISTRY, 2020, 27 (20) : 3386 - 3410

← 1 2 3 4 5 →